International and domestic tax issues. OBBB.
2025 · 2nd Quarter (Apr 1 - June 30)
ELI LILLY & COMPANY
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- ELI LILLY & COMPANY
- Filing UUID
- f087583c-2cd7-4bec-b805-4d192d45001e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General education about policies impacting pharmaceutical development and approval. Policies impacting pharmaceutical research, development, and approval. Policies impacting public health preparedness and prevention, 340B Program. Accelerated Approval pathway; Alzheimers diagnostics policies. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN.
Literal federal measure citations: H.R. 1
Policies impacting Medicare Part D and Part B reimbursement policies. "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. Treat and Reduce Obesity Act of 2023. HR. 1, One Big Beautiful Bill Act, MFN drug pricing proposals.
Literal federal measure citations: HR. 1
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
Issues related to pharmaceutical manufacturing and development. Tariffs.
Issues related to pharmaceutical manufacturing and development.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.